Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative,Randomized Parallel group,Multicentric Prospective Phase III Clinical trial of FDC of Tolperisone Hcl SR 450mg+ Diclofenac sodium SR100mg tablet OD compared with Tolperisone Hcl 150mg tablet TID for 7 Days in Patients Suffering with Acute Non Specific Low Back Pain.

X
Trial Profile

Comparative,Randomized Parallel group,Multicentric Prospective Phase III Clinical trial of FDC of Tolperisone Hcl SR 450mg+ Diclofenac sodium SR100mg tablet OD compared with Tolperisone Hcl 150mg tablet TID for 7 Days in Patients Suffering with Acute Non Specific Low Back Pain.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac/tolperisone (Primary) ; Tolperisone (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2012 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
    • 28 Nov 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top